Gastric Cancer
Gastric adenocarcinoma treated by PN401, 5-FU, and leucovorin
Published in Gastroenterology Week, October 30th, 2006
"From February, 2001 to September, 2002, the Southwest Oncology Group (SWOG) accrued 65 patients with advanced gastric adenocarcinoma to a phase II trial of weekly 5-FU, leucovorin, and the orally-administered uridine analog PN401. Of these 65 patients, 57 were assessable for survival and toxicity, which were the endpoints for the study," scientists in the United States reported.
"Treatment consisted of the administration of 1200 mg/m2 of 5-FU, 500 mg/m2 of leucovorin, and 6 grams of PN401 every 8 h, beginning 8 h after...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
More Articles from Gastroenterology Week
- Cancer Therapy
Liver radiofrequency ablation near the portal and the hepatic veins is tested - Endocrinology
During acute glucose deprivation increased ATP-sensitive K+ channel expression is observed - Gastric Lymphoma
New gastric lymphoma prognostic model proposed - Abdominal Pain
New research on abdominal pain in adolescents from University of Washington, Department of Psychology summarized - Abdominal Pain
Research on abdominal pain discussed by scientists at Osaka Medical Center, Department of Obstetrics - Abdominal Pain Cell Biology
Scientists at Hacettepe University, Department of Anesthesiology and Reanimation target abdominal pain cell biology - More from this issue of Gastroenterology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
